Coronavirus Disease 2019 in Pediatric Oncology Patients: A Matched-Cohort Analysis of the SCCM Discovery Viral Infection and Respiratory Illness Universal Study COVID-19 Registry.
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
received:
14
03
2022
accepted:
10
10
2022
pmc-release:
01
04
2024
pubmed:
3
2
2023
medline:
28
3
2023
entrez:
2
2
2023
Statut:
ppublish
Résumé
There is a paucity of multicenter data describing the impact of coronavirus disease 2019 (COVID-19) on hospitalized pediatric oncology patients. Using a large, multicenter, Society of Critical Care Medicine (SCCM) Discovery Viral Infection and Respiratory Illness University Study (VIRUS) database, we aimed at assessing outcomes of COVID-19 infection in this population. This is a matched-cohort study involving children below 18 years of age hospitalized with COVID-19 between March 2020 and January 2021. Using the VIRUS; COVID-19 Registry database, children with oncologic diseases were compared with propensity score matched (age groups, sex, race, and ethnicity) cohort of children without oncologic diseases for the prevalence of Multisystem Inflammatory Syndrome in Children (MIS-C), intensive care unit (ICU) admission, interventions, hospital, and ICU length of stay. The number of children in the case and control groups was 45 and 180, respectively. ICU admission rate was similar in both groups ([47.7 vs 51.7%], P =0.63). The proportion of children requiring noninvasive and invasive mechanical ventilation, and its duration were similar between groups, same as hospital mortality. Interestingly, MIS-C was significantly lower in the oncology group compared with the control (2.4 vs 24.6%; P =0.0002). In this study using a multicenter VIRUS database, ICU admission rate, interventions, and outcomes of COVID-19 were similar in children with the oncologic disease compared with control patients. The incidence of MIS-C is lower in oncologic patients.
Sections du résumé
BACKGROUND
There is a paucity of multicenter data describing the impact of coronavirus disease 2019 (COVID-19) on hospitalized pediatric oncology patients. Using a large, multicenter, Society of Critical Care Medicine (SCCM) Discovery Viral Infection and Respiratory Illness University Study (VIRUS) database, we aimed at assessing outcomes of COVID-19 infection in this population.
METHOD
This is a matched-cohort study involving children below 18 years of age hospitalized with COVID-19 between March 2020 and January 2021. Using the VIRUS; COVID-19 Registry database, children with oncologic diseases were compared with propensity score matched (age groups, sex, race, and ethnicity) cohort of children without oncologic diseases for the prevalence of Multisystem Inflammatory Syndrome in Children (MIS-C), intensive care unit (ICU) admission, interventions, hospital, and ICU length of stay.
RESULTS
The number of children in the case and control groups was 45 and 180, respectively. ICU admission rate was similar in both groups ([47.7 vs 51.7%], P =0.63). The proportion of children requiring noninvasive and invasive mechanical ventilation, and its duration were similar between groups, same as hospital mortality. Interestingly, MIS-C was significantly lower in the oncology group compared with the control (2.4 vs 24.6%; P =0.0002).
CONCLUSIONS
In this study using a multicenter VIRUS database, ICU admission rate, interventions, and outcomes of COVID-19 were similar in children with the oncologic disease compared with control patients. The incidence of MIS-C is lower in oncologic patients.
Identifiants
pubmed: 36729758
doi: 10.1097/MPH.0000000000002588
pii: 00043426-202304000-00016
pmc: PMC10038816
mid: NIHMS1842728
doi:
Types de publication
Multicenter Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e309-e314Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002377
Pays : United States
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
CDC. COVID Data Tracker. Available at: https://covid.cdc. gov/covid-data-tracker/#demographics . Accessed December 1, 2021.
Rüthrich MM, Giessen-Jung C, Borgmann S, et al. COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry. Ann Hematol. 2021;100:383–393.
Nguyen NT, Chinn J, Nahmias J, et al. Outcomes and mortality among adults hospitalized with COVID-19 at US medical centers. JAMA Netw Open. 2021;4:e210417.
Bhalala US, Gist KM, Tripathi S, et al. Characterization and outcomes of hospitalized children with coronavirus disease 2019: a report from a multicenter, viral infection and respiratory illness universal study (coronavirus disease 2019) registry [published online ahead of print, 2021 Aug 16]. Crit Care Med. 2022;50:e40–e51.
Shane AL, Sato AI, Kao C, et al. A pediatric infectious diseases perspective of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and novel coronavirus disease 2019 (COVID-19) in children. J Pediatric Infect Dis Soc. 2020;9:596–608.
Wood WA, Neuberg DS, Thompson JC, et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv. 2020;4:5966–5975.
Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–2892.
Madhusoodhan PP, Pierro J, Musante J, et al. Characterization of COVID-19 disease in pediatric oncology patients: the New York-New Jersey regional experience. Pediatr Blood Cancer. 2021;68:e28843.
Walkey AJ, Kumar VK, Harhay MO, et al. The viral infection and respiratory illness universal study (VIRUS): an international registry of coronavirus 2019-related critical illness. Crit Care Explor. 2020;2:e0113.
Walkey AJ, Sheldrick RC, Kashyap R, et al. Guiding principles for the conduct of observational critical care research for coronavirus disease 2019 pandemics and beyond: the society of critical care medicine discovery viral infection and respiratory illness universal study registry. Crit Care Med. 2020;48:e1038–e1044.
Harris PA, Taylor R, Thielke R, et al. Conde, research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–381.
CDC. Information for Healthcare Providers about Multisystem Inflammatory Syndrome in Children (MIS-C). Available at: https://www.cdc.gov/mis/mis-c/hcp/index.html . Accessed August, 2022.
Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–337.
Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10:783–791.
Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study [published correction appears in Lancet. 2020 Sep 12;396(10253):758]. Lancet. 2020;395:1907–1918.
Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020;109:1088–1095.
Cruz AT, Zeichner SL. COVID-19 in children: initial characterization of the pediatric disease. Pediatrics. 2020;145:e20200834.
Ogimi C, Englund JA, Bradford MC, et al. Characteristics and outcomes of coronavirus infection in children: the role of viral factors and an immunocompromised state. J Pediatric Infect Dis Soc. 2019;8:21–28.
Boulad F, Kamboj M, Bouvier N, et al. COVID-19 in children with cancer in New York city. JAMA Oncol. 2020;6:1459–1460.
ASH Research Collaborative. COVID‐19 Registry. Updated: October 28, 2021. Available at: https://www.ashresearchcollaborative.org/s/covid-19-registry . Accessed August, 2022.
UAB. The Pediatric COVID‐19 Cancer Case Report. 2020. Available at: https://www.uab.edu/medicine/icos/icos‐research/the‐pocc‐report . Accessed August, 2022.
St. Jude Global. Global Registry of COVID‐19 in Pediatric Cancer. 2020. Available at: https://global.stjude.org/en-us/global-covid-19-observatory-and-resource-center-for-childhood-cancer/registry.html . Accessed August, 2022.
Faura A, Rives S, Lassaletta Á, et al. Initial report on Spanish pediatric oncologic, hematologic, and post stem cell transplantation patients during SARS-CoV-2 pandemic. Pediatr Blood Cancer. 2020;67:e28557.
D’Antiga L. Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transpl. 2020;26:832–834.
Chen Z, Xiong H, Li JX, et al. COVID-19 with postchemotherapy agranulocytosis in childhood acute leukemia: a case report. Chinese J Hematol. 2020;41:341–343.
André N, Rouger-Gaudichon J, Brethon B, et al. COVID-19 in pediatric oncology from French pediatric oncology and hematology centers: high risk of severe forms? Pediatr Blood Cancer. 2020;67:e28392.
Millen GC, Arnold R, Cazier JB, et al. Severity of COVID-19 in children with cancer: report from the United Kingdom paediatric coronavirus cancer monitoring project. Br J Cancer. 2021;124:754–759.
Goudouris ES, Pinto-Mariz F, Mendonça LO, et al. Outcome of SARS-CoV-2 infection in 121 patients with inborn errors of immunity: a cross-sectional study. J Clin Immunol. 2021;41:1479–1489.
Consiglio CR, Cotugno N, Sardh F, et al. The immunology of multisystem inflammatory syndrome in children with COVID-19. Cell. 2020;183:968–981.e7.
Simpson JM, Newburger JW. Multisystem inflammatory syndrome in children in association with COVID-19. Circulation. 2020;142:437–440.
Garcia-Vidal C, Sanjuan G, Moreno-García E, et al. Incidence of coinfections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021;27:83–88.
Lansbury L, Lim B, Baskaran V, et al. Coinfections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020;81:266–275.